Market Cap
US$12.1b
Last Updated
2020/09/20 05:56 UTC
Data Sources
Company Financials +
Executive Summary
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. More Details
Snowflake Analysis
Questionable track record with limited growth.
Similar Companies
Share Price & News
How has Waters's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: WAT has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-4.1%
WAT
-1.5%
US Life Sciences
0.09%
US Market
1 Year Return
-14.5%
WAT
30.1%
US Life Sciences
12.6%
US Market
Return vs Industry: WAT underperformed the US Life Sciences industry which returned 30.1% over the past year.
Return vs Market: WAT underperformed the US Market which returned 12.6% over the past year.
Shareholder returns
| WAT | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.1% | -1.5% | 0.09% |
| 30 Day | -9.6% | -1.2% | -1.6% |
| 90 Day | 5.3% | 13.2% | 7.9% |
| 1 Year | -14.5%-14.5% | 30.3%30.1% | 15.2%12.6% |
| 3 Year | 7.9%7.9% | 88.1%86.9% | 38.9%29.6% |
| 5 Year | 66.8%66.8% | 177.7%174.2% | 87.6%66.5% |
Price Volatility Vs. Market
How volatile is Waters's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
If You Had Bought Waters (NYSE:WAT) Stock Five Years Ago, You Could Pocket A 74% Gain Today3 weeks ago | Simply Wall St
When Should You Buy Waters Corporation (NYSE:WAT)?1 month ago | Simply Wall St
Some Shareholders Feeling Restless Over Waters Corporation's (NYSE:WAT) P/E RatioValuation
Is Waters undervalued compared to its fair value and its price relative to the market?
24.09x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: WAT ($195.47) is trading above our estimate of fair value ($151.23)
Significantly Below Fair Value: WAT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: WAT is good value based on its PE Ratio (24.1x) compared to the US Life Sciences industry average (41.9x).
PE vs Market: WAT is poor value based on its PE Ratio (24.1x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: WAT is poor value based on its PEG Ratio (2x)
Price to Book Ratio
PB vs Industry: WAT has negative assets, so we can't compare its PB Ratio to the US Life Sciences industry average.
Next Steps
Future Growth
How is Waters forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
11.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: WAT's forecast earnings growth (11.8% per year) is above the savings rate (2.2%).
Earnings vs Market: WAT's earnings (11.8% per year) are forecast to grow slower than the US market (23.2% per year).
High Growth Earnings: WAT's earnings are forecast to grow, but not significantly.
Revenue vs Market: WAT's revenue (5.8% per year) is forecast to grow slower than the US market (9.7% per year).
High Growth Revenue: WAT's revenue (5.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: WAT's Return on Equity is forecast to be very high in 3 years time (331.9%).
Next Steps
Past Performance
How has Waters performed over the past 5 years?
1.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: WAT has high quality earnings.
Growing Profit Margin: WAT's current net profit margins (22.6%) are lower than last year (24.1%).
Past Earnings Growth Analysis
Earnings Trend: WAT's earnings have grown by 1.5% per year over the past 5 years.
Accelerating Growth: WAT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: WAT had negative earnings growth (-11.1%) over the past year, making it difficult to compare to the Life Sciences industry average (14.9%).
Return on Equity
High ROE: WAT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Next Steps
Financial Health
How is Waters's financial position?
Financial Position Analysis
Short Term Liabilities: WAT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: WAT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: WAT has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: WAT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: WAT's debt is well covered by operating cash flow (40.7%).
Interest Coverage: WAT's interest payments on its debt are well covered by EBIT (18x coverage).
Balance Sheet
Next Steps
Dividend
What is Waters's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate WAT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate WAT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if WAT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if WAT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of WAT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.9yrs
Average management tenure
CEO
Udit Batra (49 yo)
no data
Tenure
Dr. Udit Batra, PhD, serves as President, Chief Executive Officer and Director at Waters Corporation since September 1, 2020. Dr. Batra served as Chief Executive Officer of Life Science business of Merck a ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Senior VP & CFO | 3.67yrs | US$559.22k | 0.0060% $ 727.5k | |
| Senior VP | 0.92yr | US$1.07m | 0.00097% $ 117.4k | |
| no data | US$1.08m | no data | ||
| Senior Vice President of Global Markets | 4.58yrs | US$521.97k | 0.0037% $ 446.7k | |
| Senior VP & President of TA Instruments | 1.08yrs | US$872.26k | 0.0020% $ 238.5k | |
| President | no data | no data | no data | |
| Senior Vice President of Global Operations | 0.083yr | no data | 0.0042% $ 508.4k | |
| Senior Director of Investor Relations | no data | no data | no data | |
| Senior Director of Public Relations | no data | no data | no data | |
| Senior Vice President of Corporate Development | 2.58yrs | US$3.78m | 0.0019% $ 230.0k | |
| Senior Vice President of Global Human Resources | 4.58yrs | US$1.58m | 0.022% $ 2.7m | |
| Senior Vice President of Global Products | 3.17yrs | US$2.17m | 0.0084% $ 1.0m |
2.9yrs
Average Tenure
53yo
Average Age
Experienced Management: WAT's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | no data | no data | |
| Independent Director | 26.08yrs | US$314.86k | 0.11% $ 13.3m | |
| Independent Director | 2yrs | US$298.86k | 0.0022% $ 265.1k | |
| Independent Director | 14.33yrs | US$323.36k | 0.026% $ 3.2m | |
| Independent Director | 22.5yrs | US$306.36k | 0.035% $ 4.3m | |
| Lead Independent Director | 16.58yrs | US$324.36k | 0.16% $ 19.4m | |
| Independent Director | 14.33yrs | US$325.86k | 0.052% $ 6.3m | |
| Independent Director | 2yrs | US$300.36k | 0.0025% $ 301.4k | |
| Independent Chairman | 0.50yr | US$318.86k | 0.0047% $ 570.1k |
14.3yrs
Average Tenure
63yo
Average Age
Experienced Board: WAT's board of directors are seasoned and experienced ( 14.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: WAT insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Waters Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Waters Corporation
- Ticker: WAT
- Exchange: NYSE
- Founded: 1958
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$12.105b
- Shares outstanding: 61.93m
- Website: https://www.waters.com
Number of Employees
Location
- Waters Corporation
- 34 Maple Street
- Milford
- Massachusetts
- 1757
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| WAT | NYSE (New York Stock Exchange) | Yes | Common Shares | US | USD | Nov 1995 |
| WAZ | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Nov 1995 |
| 0LTI | LSE (London Stock Exchange) | Yes | Common Shares | GB | USD | Nov 1995 |
| WAT * | BMV (Bolsa Mexicana de Valores) | Yes | Common Shares | MX | MXN | Nov 1995 |
| WATC34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH 1 REP 0.25 COM USD0.01 | BR | BRL | May 2019 |
Biography
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufact ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/09/20 05:56 |
| End of Day Share Price | 2020/09/18 00:00 |
| Earnings | 2020/06/27 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.